135 related articles for article (PubMed ID: 38378388)
1. Liposomal co-encapsulation of a novel gemini lipopeptide and a CpG-ODN induces a strong Th1 response with the co-activation of a Th2/Th17 profile and high antibody levels.
Reidel IG; Curti CC; Dorémus L; Béré E; Delwail A; Russi RC; Lecron JC; Morel F; García MI; Müller DM; Jégou JF; Veaute CM
Vaccine; 2024 Mar; 42(8):1953-1965. PubMed ID: 38378388
[TBL] [Abstract][Full Text] [Related]
2. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
[TBL] [Abstract][Full Text] [Related]
3. Liposomal and CpG-ODN formulation elicits strong humoral immune responses to recombinant Staphylococcus aureus antigens in heifer calves.
Reidel IG; Camussone C; Suarez Archilla GA; Calvinho LF; Veaute C
Vet Immunol Immunopathol; 2019 Jun; 212():1-8. PubMed ID: 31213246
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant activity of CpG-ODN formulated as a liquid crystal.
Sánchez Vallecillo MF; Ullio Gamboa GV; Palma SD; Harman MF; Chiodetti AL; Morón G; Allemandi DA; Pistoresi-Palencia MC; Maletto BA
Biomaterials; 2014 Mar; 35(8):2529-42. PubMed ID: 24382332
[TBL] [Abstract][Full Text] [Related]
5. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines.
Joseph A; Louria-Hayon I; Plis-Finarov A; Zeira E; Zakay-Rones Z; Raz E; Hayashi T; Takabayashi K; Barenholz Y; Kedar E
Vaccine; 2002 Sep; 20(27-28):3342-54. PubMed ID: 12213404
[TBL] [Abstract][Full Text] [Related]
6. Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice.
Badiee A; Jaafari MR; Samiei A; Soroush D; Khamesipour A
Clin Vaccine Immunol; 2008 Apr; 15(4):668-74. PubMed ID: 18235040
[TBL] [Abstract][Full Text] [Related]
7. Polymeric antigen BLSOmp31 formulated with class B CpG-ODN in a nanostructure (BLSOmp31/CpG-ODN/Coa-ASC16) administered by parenteral or mucosal routes confers protection against Brucella ovis in Balb/c mice.
Moran MC; Bence AR; Vallecillo MFS; Lützelschwab CM; Rodriguez MG; Pardo R; Goldbaum FA; Zylberman V; Palma SD; Maletto BA; Estein SM
Res Vet Sci; 2021 Mar; 135():217-227. PubMed ID: 33631456
[TBL] [Abstract][Full Text] [Related]
8. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.
Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ
Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256
[TBL] [Abstract][Full Text] [Related]
9. A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine.
Sugai T; Mori M; Nakazawa M; Ichino M; Naruto T; Kobayashi N; Kobayashi Y; Minami M; Yokota S
Vaccine; 2005 Nov; 23(46-47):5450-6. PubMed ID: 16006019
[TBL] [Abstract][Full Text] [Related]
10. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
[TBL] [Abstract][Full Text] [Related]
11. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.
Chu RS; Targoni OS; Krieg AM; Lehmann PV; Harding CV
J Exp Med; 1997 Nov; 186(10):1623-31. PubMed ID: 9362523
[TBL] [Abstract][Full Text] [Related]
12. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
Mutwiri G; Benjamin P; Soita H; Babiuk LA
Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
[TBL] [Abstract][Full Text] [Related]
13. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein.
Ioannou XP; Gomis SM; Karvonen B; Hecker R; Babiuk LA; van Drunen Littel-van den Hurk S
Vaccine; 2002 Nov; 21(1-2):127-37. PubMed ID: 12443671
[TBL] [Abstract][Full Text] [Related]
14. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies.
Chu RS; McCool T; Greenspan NS; Schreiber JR; Harding CV
Infect Immun; 2000 Mar; 68(3):1450-6. PubMed ID: 10678959
[TBL] [Abstract][Full Text] [Related]
15. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution.
McCluskie MJ; Weeratna RD; Davis HL
Mol Med; 2000 Oct; 6(10):867-77. PubMed ID: 11126201
[TBL] [Abstract][Full Text] [Related]
16. Class-B CpG-ODN Formulated With a Nanostructure Induces Type I Interferons-Dependent and CD4
Chiodetti AL; Sánchez Vallecillo MF; Dolina JS; Crespo MI; Marin C; Schoenberger SP; Allemandi DA; Palma SD; Pistoresi-Palencia MC; Morón G; Maletto BA
Front Immunol; 2018; 9():2319. PubMed ID: 30364187
[TBL] [Abstract][Full Text] [Related]
17. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.
Jaafari MR; Badiee A; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
Vaccine; 2007 Aug; 25(32):6107-17. PubMed ID: 17629372
[TBL] [Abstract][Full Text] [Related]
18. [CpG-ODN is a potential candidate adjuvant for human vaccines].
Xu H; Wang S; Guo F; Lu R; Ruan L
Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):553-6. PubMed ID: 12133504
[TBL] [Abstract][Full Text] [Related]
19. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
[TBL] [Abstract][Full Text] [Related]
20. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
Davis HL; Weeratna R; Waldschmidt TJ; Tygrett L; Schorr J; Krieg AM
J Immunol; 1998 Jan; 160(2):870-6. PubMed ID: 9551923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
